Up to 30% of RCC overexpressed PD-L1 [12]. Higher expression of PD-L1 was associated with adverse clinicopathological features: poorly differentiated cells, necrosis, and sarcomatoid differentiation [13]. In some malignancies, the tumor PD-L1 expression can predict the response to anti-PD-1/PD-L1 therapy. This evidence concerns the gene CD274 and neoplasm.